- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00558545
A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer
30 novembre 2009 mis à jour par: Aegera Therapeutics
A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer
This is an open-label multicenter, phase 1-2 study.
Following determination of the recommended AEG35156 dose in combination with weekly paclitaxel in the initial Phase 1 part of this study, additional patients will be enrolled in the Phase 2 part of the study to assess the activity of the combination in advanced breast cancer.
Aperçu de l'étude
Statut
Résilié
Les conditions
Intervention / Traitement
Description détaillée
Breast cancer is the most common cancer in women in the United States, the second most common cause of cancer death, and the main cause of death in women ages 45 to 55.
In 2006, 212,920 American women will be diagnosed with breast cancer, and 40,970 will die from this disease.[1].
Fewer than 10 percent of women present with metastatic disease at the time of diagnosis.
However, the majority of women who relapse after initial definitive therapy for early stage or locally advanced disease will do so with disseminated metastatic disease rather than an isolated local recurrence.
Treatment for metastatic disease is palliative in intent and will usually involve hormone therapy and/or chemotherapy with or without trastuzumab.
Active chemotherapy agents include anthracyclines, taxanes, vinorelbine, alkylating agents and antimetabolites.
Taxanes have become the cornerstone of first-line treatment for metastatic breast cancer.
Weekly doses of paclitaxel can be administered continuously for several weeks with a remarkable lack of myelosuppression [2].
Weekly paclitaxel (80 mg/m2) was directly compared to every three-week therapy (175 mg/m2) in 585 women with metastatic breast cancer.
Weekly therapy was associated with a significantly higher response rate (40 versus 28 percent) and longer TTP (nine versus five months), but similar overall survival and worse neurotoxicity [3].
Since patients with metastatic breast cancer are unlikely to be cured of their disease [4], they should be considered candidates for a clinical trial.
Type d'étude
Interventionnel
Inscription (Anticipé)
61
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Colorado
-
Denver, Colorado, États-Unis, 80218
- Rocky Mountain Cancer Center
-
-
Florida
-
Ocoee, Florida, États-Unis, 34761
- Cancer Centers of Florida, P.A.
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46219
- Central Indiana Cancer Center
-
-
New York
-
Albany, New York, États-Unis, 12206
- New York Oncology & Hematology P. C., Albany Cancer Center
-
-
Ohio
-
Dayton, Ohio, États-Unis, 45409
- Dayton Oncology & Hematology, P.A.
-
-
South Carolina
-
Greenville, South Carolina, États-Unis, 29605
- Cancer Centers of the Carolinas
-
-
Texas
-
Dallas, Texas, États-Unis, 75246
- Sammons Cancer Center
-
Tyler, Texas, États-Unis, 75702
- Tyler Cancer Center
-
-
Virginia
-
Norfolk, Virginia, États-Unis, 23502
- Virginia Oncology Associates
-
-
Washington
-
Vancouver, Washington, États-Unis, 98684
- Northwest Cancer Specialists, P. C.
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Patients with histologically or cytologically confirmed breast adenocarcinoma who are candidates for paclitaxel single agent chemotherapy for metastatic breast cancer
- ECOG performance < 2
- One or more metastatic tumors measurable by RECIST criteria on CT scan or MRI (Phase 2 part only)
- Life expectancy of at least 6 months
- Age > 18 years
- Signed, written IRB-approved informed consent
- A negative serum pregnancy test (if applicable)
- Acceptable liver function:
- Bilirubin within normal limit
- AST (SGOT), ALT (SGPT) and Alkaline phosphatase < 2.0 times the institution's upper limit of normal
- Acceptable renal function:
- Serum creatinine within normal limits, OR calculated creatinine clearance > 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
- Acceptable hematologic status:
- Granulocyte > 1500 cells/uL
- Platelet count > 100,000 plt/uL
- Hemoglobin > 9.0 g/dL
- Acceptable coagulation status:
- PT within normal limits
- PTT within normal limits
- For women of child-bearing potential, the use of effective contraceptive methods during the study
- Prior radiotherapy is allowed provided disease progression outside the radiation field has been documented, and treatment completed at least 2 weeks prior to registration
Exclusion Criteria:
- Prior taxane chemotherapy for metastatic disease.
- More than one prior chemotherapy regimen for metastatic disease
- Active progressive brain metastases including the presence of any related symptoms or need for corticosteroids. A CT or MRI scan of the head is necessary in patients with a history of brain metastases to document the stability of prior lesions
- Grade > 2 peripheral neuropathy
- Known bleeding diathesis or concurrent treatment with anticoagulants except patients on non-therapeutic line maintenance coumadin
- Pregnant or nursing women. NOTE: Women of child-bearing potential must agree to use adequate contraception (sterile or surgically sterile; hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- Known infection with HIV, hepatitis B, or hepatitis C
- Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor
- Patients who are currently receiving any other investigational agent. Subjects who have used a previous antisense oligonucleotide in the last 90 days will be excluded
- Unwillingness or inability to comply with procedures required in this protocol
- Any deviation from these inclusion/exclusion criteria must be discussed with the sponsor prior to enrolling patient.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
To determine the recommended dose of AEG35156 when used in combination with weekly paclitaxel and at the dose enhance the clinical benefit rate (CBR) of paclitaxel in patients with advanced breast cancer.
Délai: 2 years
|
2 years
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Déterminer la survie sans progression.
Délai: 2 années
|
2 années
|
|
To establish the pharmacokinetics of AEG35156 and paclitaxel when used in combination.
Délai: 2 years
|
2 years
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Directeur d'études: Jacques Jolivet, MD, FACP, Aegera Therapeutics, Inc.
- Chercheur principal: David M Loesch, MD, Central Indiana Cancer Centers
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30. doi: 10.3322/canjclin.56.2.106.
- Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996 Aug;14(8):2197-205. doi: 10.1200/JCO.1996.14.8.2197.
- Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001 Nov 15;19(22):4216-23. doi: 10.1200/JCO.2001.19.22.4216.
- Seidman, A., et al., CALGB 9840: Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol, 2004. 23: p. 6s.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 novembre 2007
Achèvement primaire (Réel)
1 mai 2009
Achèvement de l'étude (Réel)
1 mai 2009
Dates d'inscription aux études
Première soumission
13 novembre 2007
Première soumission répondant aux critères de contrôle qualité
13 novembre 2007
Première publication (Estimation)
15 novembre 2007
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
2 décembre 2009
Dernière mise à jour soumise répondant aux critères de contrôle qualité
30 novembre 2009
Dernière vérification
1 novembre 2009
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AEG35156-202
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .